Vedolizumab Induction May Prevent Celiac Enteritis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

1 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-06-25

Study Completion Date

2018-10-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Celiac disease (CD) is characterized as an autoimmune disorder whereby gluten (a protein found in wheat, barley, rye, malt) induces an immunological response in genetically susceptible individuals. The prevalence of CD has been estimated to affect 0.5-1% of the population worldwide. Long term sequelae are numerous and include risk of lymphoma, malabsorption leading to weight loss, anemia, multiple vitamin deficiencies, osteoporosis/osteopenia, secondary autoimmunity, etc. (1)

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Celiac Disease Prevention

NCT00617838

Celiac Disease

UNKNOWN NA

Validation of a New Innovative Method for Specific Marker Detection in Celiac Disease

NCT06324539

Celiac Disease in Children

RECRUITING

Assessment of Immune Activation and Tolerance in Celiac Disease During Gluten Challenge

NCT03409796

Celiac Disease

COMPLETED NA

Safety and Tolerability of Nexvax2 in Subjects With Celiac Disease

NCT02528799

Celiac Disease

COMPLETED PHASE1

Serum Markers in Gluten Challenge

NCT00931892

Celiac Disease

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Adult subjects with CD will be recruited through our clinic. All patients enrolled will have established CD diagnosed \> 6 months. All patients will have history of abnormal MARSH score on initial duodenal biopsy at diagnosis and MARSH 0 on repeat biopsy following a gluten free diet (GFD). All patients will also have positive celiac serologies (anti-TTG, anti-gliadin, etc.) at diagnosis, as well as, positive HLA DQ2/DQ8 genetic profile. At enrollment, all patients will have negative celiac serologies, indicative of serologic remission on a gluten free diet. Female subjects of childbearing potential (does not include those with history of tubal ligation/surgical sterilization, hysterectomy and/or oophorectomy) who are sexually active with a non-sterilized male partners agree to routinely use adequate contraception from signing informed consent, during study process and for an additional 18 weeks after the last dose of vedolizumab. A male subject who is non-sterilized and sexually active with a female partner of childbearing potential agrees to use adequate contraception from signing informed consent throughout the duration of the study and for 18 weeks after the last dose.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Celiac Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vedolizumab

Vedolizumab (Entyvio) 300mg IV at week 0, 2 and 6

Group Type EXPERIMENTAL

Vedolizumab

Intervention Type DRUG

IV infusion week 0, 2 and 6

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vedolizumab

IV infusion week 0, 2 and 6

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Entyvio

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients must meet the following criteria for study entry:
* Adult patients with Celiac Disease (CD)
* Without any additional co-morbidities
* Normal renal and hepatic function
* Diagnosis of CD established at least 6 months prior to trial with diagnostic serology, genetic profile, endoscopic appearance and histopathology report In histologic and serologic remission (defined as MARSH 0 and negative anti-tissue transglutaminase, etc.) following a gluten free diet
* Naïve to treatment with vedolizumab
* Able and willing to provide written informed consent
* Eligibility criteria for laboratory profiles - healthy patient normal laboratory reference values

* WBC 4.5-12.0 k/UL
* Platelet count- 140-415 k/UL
* Hemoglobin- 11.0-17.4 %g/dL
* Renal Function-
* Creatinine- 0.5-1.3 mg/dL
* BUN- 5-20 mg/dL
* Hepatic Function
* Albumin - 3.3-5.0 g/dL
* INR- 0.9-1.1
* AST- 0-37 U/L
* ALT- 0-40 U/L
* Total Bilirubin- 0.1-1.3 mg/dL
* Alk Phos- 35-150 U/L

Exclusion Criteria

* Patients who meet any of the following criteria will be excluded from study entry:
* Abnormal MARSH score on enrollment histopathology
* Elevated celiac serologies (anti-tissue transglutaminase, etc.)
* Current use of biologics or immunomodulators Adalimumab, infliximab, Ustekinumab, Golimumab, Tocilizumab, Certolizumab, Etanercept, Rituximab, Anakinra, Abatacept, Tofacitinib, Methotrexate, Azathioprine, 6-MP.
* Current use of immunosuppressive therapy including intermittent systemic corticosteroids within two months of vedolizumab induction
* History of intestinal lymphoma (MALToma, etc.)
* History of cancer including hematologic malignancy, solid tumors, carcinoma in situ, etc.
* Pregnant or lactating
* Fertile females will require at least one form of birth control
* Lack of peripheral venous access
* Inability to comply with study protocol, in the opinion of the investigator
* Neurological conditions which may interfere with monitoring for PML
* History of demyelinating disease or history of major neurological disease
* History of alcohol, drug or chemical abuse \< 6 months prior to screening
* History of active tuberculosis (TB) or a positive screening test for latent mycobacterium tuberculosis infection
* Positive PPD= \> 10 mm or \> 5mm in patients on 15 mg or more of prednisone
* History of BCG vaccination should be screened using Quantiferon TB Gold test
* An Indeterminate Quantiferon test will require a chest X-ray to rule out active TB and consultation with an infectious disease specialist to confirm the risk of latent
* TB is low and that patients can be safely enrolled in the trial
* History of recurrent opportunistic infections and/or of severe or disseminated viral infections
* Active autoimmune disease
* Active inflammatory bowel disease

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes